1.Role of B-cell-activating-factor in immune regulation--review.
Jian-Fang DU ; Jia-Xi WANG ; Dong-Gang XU
Journal of Experimental Hematology 2006;14(3):631-634
B cell activating factor (BAFF) is one of the TNF family member, regulates the survival and maturation of B lymphocyte. BAFF binds to three receptors: BCMA, TACI and BAFF-R. In recent years, studies have revealed important roles of BAFF and its receptors in immune regulation of antibody isotype switching, germinal center maintenance, and T cell co-stimulation, that may provide new drugs in the future for the treatment of autoimmune disorders, lymphoma and B cell immunodeficiencies. Therefore, the structure, expression, receptors, biological function and clinical application of BAFF are briefly summarized in this review.
B-Cell Activating Factor
;
immunology
;
B-Cell Activation Factor Receptor
;
immunology
;
B-Cell Maturation Antigen
;
immunology
;
B-Lymphocytes
;
immunology
;
Humans
;
Immunity
;
Transmembrane Activator and CAML Interactor Protein
;
immunology
2.Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
He HUANG ; Heng-Wei WU ; Yong-Xian HU
Journal of Zhejiang University. Science. B 2020;21(1):29-41
Multiple myeloma (MM), considered an incurable hematological malignancy, is characterized by its clonal evolution of malignant plasma cells. Although the application of autologous stem cell transplantation (ASCT) and the introduction of novel agents such as immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) have doubled the median overall survival to eight years, relapsed and refractory diseases are still frequent events in the course of MM. To achieve a durable and deep remission, immunotherapy modalities have been developed for relapsed/refractory multiple myeloma (RRMM). Among these approaches, chimeric antigen receptor (CAR) T-cell therapy is the most promising star, based on the results of previous success in B-cell neoplasms. In this immunotherapy, autologous T cells are engineered to express an artificial receptor which targets a tumor-associated antigen and initiates the T-cell killing procedure. Tisagenlecleucel and Axicabtagene, targeting the CD19 antigen, are the two pacesetters of CAR T-cell products. They were approved by the US Food and Drug Administration (FDA) in 2017 for the treatment of acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Their development enabled unparalleled efficacy in combating hematopoietic neoplasms. In this review article, we summarize six promising candidate antigens in MM that can be targeted by CARs and discuss some noteworthy studies of the safety profile of current CAR T-cell therapy.
ADP-ribosyl Cyclase 1/immunology*
;
B-Cell Maturation Antigen/immunology*
;
Humans
;
Immunotherapy, Adoptive/methods*
;
Multiple Myeloma/therapy*
;
Receptors, Chimeric Antigen/immunology*
;
Receptors, G-Protein-Coupled/immunology*
;
Signaling Lymphocytic Activation Molecule Family/immunology*
;
Syndecan-1/immunology*
;
T-Lymphocytes/immunology*